Literature DB >> 29435288

A post-recurrence survival-predicting indicator for cervical cancer from the analysis of 165 patients who developed recurrence.

Kosuke Yoshida1, Hiroaki Kajiyama1, Fumi Utsumi1, Kaoru Niimi1, Jun Sakata1, Shiro Suzuki1, Kiyosumi Shibata2, Fumitaka Kikkawa1.   

Abstract

The aim of the present study was to estimate the post-recurrence survival (PRS) of patients with relapsed uterine cervical cancer (RUCC). In addition, clinicopathological indicators that influenced PRS were investigated. Between 1998 and 2014, of 740 patients with cervical cancer, 165 patients experienced recurrence (recurrence rate, 22.3%), and 83 patients succumbed to the disease within a median follow-up of 34.3 months. A total of 151 stage Ib-IV patients who experienced recurrence after initial treatment for cervical cancer at our institute were analyzed. Uni- and multivariate analyses were performed using the Kaplan Meier method, and Cox regression model. The median age was 55 years (range, 20-88 years). In all, 80 patients succumbed to the disease. The median PRS time of all the patients was 28.4 months. The 1-, 3-, and 5-year PRS rates of patients were 75.1, 41.9, and 32.1%, respectively. In addition, the median survival period in patients who had received surgery as an initial treatment was significantly longer compared with that in patients who had not previously undergone surgery (36.7 vs. 23.3 months, respectively; P=0.0338). Following the univariate analysis, the median PRS in patients with in- and out-field recurrence was 12.6, and 45.9 months, respectively (P<0.0001). Furthermore, in the multivariable analysis, the recurrence site was a significant prognostic indicator of PRS [(In-field vs. Out-field); hazard ratio, 2.848; 95% confidence interval, 1.707-4.738; P<0.0001]. The long-term clinical outcome of patients with RUCC was poor. In particular, the in-field recurrence was identified to be associated with poor post-recurrence oncological outcome in patients with RUCC.

Entities:  

Keywords:  cervical cancer; in-field recurrence; post-recurrence survival; salvage treatment

Year:  2017        PMID: 29435288      PMCID: PMC5776414          DOI: 10.3892/mco.2017.1530

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  20 in total

1.  Extended pelvic resections for recurrent or persistent uterine and cervical malignancies: an update on out of the box surgery.

Authors:  V Andikyan; F Khoury-Collado; Y Sonoda; S R Gerst; K M Alektiar; J S Sandhu; B H Bochner; R R Barakat; P J Boland; D S Chi
Journal:  Gynecol Oncol       Date:  2012-01-28       Impact factor: 5.482

2.  Cervix carcinoma, concurrent chemoradiotherapy, and salvage of isolated paraaortic lymph node recurrence.

Authors:  Anurag K Singh; Perry W Grigsby; Janet S Rader; David G Mutch; Matthew A Powell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-02-01       Impact factor: 7.038

3.  Outcomes and prognosis of patients with recurrent cervical cancer after radical hysterectomy.

Authors:  Jian-Tai Qiu; Nor Anita Abdullah; Hung-Hsueh Chou; Cheng-Tao Lin; Shih-Ming Jung; Chun-Chieh Wang; Min-Yu Chen; Kuan-Gen Huang; Ting-Chang Chang; Chyong-Huey Lai
Journal:  Gynecol Oncol       Date:  2012-08-14       Impact factor: 5.482

4.  Effects of chemotherapy on patients with recurrent cervical cancer previously treated with concurrent chemoradiotherapy: a retrospective multicenter survey in Japan.

Authors:  Hideki Tokunaga; Toru Nakanishi; Takashi Iwata; Daisuke Aoki; Toshiaki Saito; Satoru Nagase; Fumiaki Takahashi; Nobuo Yaegashi; Yoh Watanabe
Journal:  Int J Clin Oncol       Date:  2014-07-16       Impact factor: 3.402

5.  Surgery versus radiation therapy for stage IB2 cervical carcinoma: a population-based analysis.

Authors:  Bunja Rungruang; Madeleine Courtney-Brooks; Sushil Beriwal; Kristin K Zorn; Scott D Richard; Alexander B Olawaiye; Thomas C Krivak; Paniti Sukumvanich
Journal:  Int J Gynecol Cancer       Date:  2012-03       Impact factor: 3.437

6.  Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.

Authors:  M Morris; P J Eifel; J Lu; P W Grigsby; C Levenback; R E Stevens; M Rotman; D M Gershenson; D G Mutch
Journal:  N Engl J Med       Date:  1999-04-15       Impact factor: 91.245

Review 7.  Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer.

Authors:  Larysa Rydzewska; Jayne Tierney; Claire L Vale; Paul R Symonds
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

8.  Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy.

Authors:  Peter G Rose; James Java; Charles W Whitney; Frederick B Stehman; Rachelle Lanciano; Gillian M Thomas; Paul A DiSilvestro
Journal:  J Clin Oncol       Date:  2015-03-02       Impact factor: 44.544

9.  Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2).

Authors:  Claudia Allemani; Hannah K Weir; Helena Carreira; Rhea Harewood; Devon Spika; Xiao-Si Wang; Finian Bannon; Jane V Ahn; Christopher J Johnson; Audrey Bonaventure; Rafael Marcos-Gragera; Charles Stiller; Gulnar Azevedo e Silva; Wan-Qing Chen; Olufemi J Ogunbiyi; Bernard Rachet; Matthew J Soeberg; Hui You; Tomohiro Matsuda; Magdalena Bielska-Lasota; Hans Storm; Thomas C Tucker; Michel P Coleman
Journal:  Lancet       Date:  2014-11-26       Impact factor: 79.321

10.  Prognostic factors and treatment outcome after radiotherapy in cervical cancer patients with isolated para-aortic lymph node metastases.

Authors:  Hyunsoo Jang; Mison Chun; Oyeon Cho; Jae Sung Heo; Hee-Sug Ryu; Suk-Joon Chang
Journal:  J Gynecol Oncol       Date:  2013-07-04       Impact factor: 4.401

View more
  12 in total

1.  The role of additional hysterectomy after concurrent chemoradiation for patients with locally advanced cervical cancer.

Authors:  Kosuke Yoshida; Hiroaki Kajiyama; Masato Yoshihara; Satoshi Tamauchi; Yoshiki Ikeda; Nobuhisa Yoshikawa; Kimihiro Nishino; Kaoru Niimi; Shiro Suzuki; Fumitaka Kikkawa
Journal:  Int J Clin Oncol       Date:  2019-09-24       Impact factor: 3.402

2.  Clinical Significance of Ubiquitin-associated Protein 2-like in Patients With Uterine Cervical Cancer.

Authors:  Kosuke Yoshida; Hiroaki Kajiyama; Eri Inami; Satoshi Tamauchi; Yoshiki Ikeda; Nobuhisa Yoshikawa; Kimihiro Nishino; Fumi Utsumi; Kaoru Niimi; Shiro Suzuki; Kiyosumi Shibata; Akihiro Nawa; Fumitaka Kikkawa
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

Review 3.  The role of imaging in pelvic exenteration for gynecological cancers.

Authors:  Pamela Ines Causa Andrieu; Sungmin Woo; Eric Rios-Doria; Yukio Sonoda; Soleen Ghafoor
Journal:  Br J Radiol       Date:  2021-05-07       Impact factor: 3.629

4.  Post-recurrence survival in patients with cervical cancer.

Authors:  David Cibula; Lukáš Dostálek; Jiri Jarkovsky; Constantijne H Mom; Aldo Lopez; Henrik Falconer; Giovanni Scambia; Ali Ayhan; Sarah H Kim; David Isla Ortiz; Jaroslav Klat; Andreas Obermair; Giampaolo Di Martino; Rene Pareja; Ranjit Manchanda; Jan Kosťun; Ricardo Dos Reis; Mehmet Mutlu Meydanli; Diego Odetto; Rene Laky; Ignacio Zapardiel; Vit Weinberger; Klára Benešová; Martina Borčinová; Fernando Cardenas; Emelie Wallin; Luigi Pedone Anchora; Huseyin Akilli; Nadeem R Abu-Rustum; Salim Abraham Barquet-Muñoz; Veronika Javůrková; Daniela Fischerová; Luc R C W van Lonkhuijzen
Journal:  Gynecol Oncol       Date:  2021-12-23       Impact factor: 5.304

5.  Prognostic Value of Restaging F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict 3-Year Post-Recurrence Survival in Patients with Recurrent Gastric Cancer after Curative Resection.

Authors:  Sung Hoon Kim; Bong Il Song; Hae Won Kim; Kyoung Sook Won; Young Gil Son; Seung Wan Ryu
Journal:  Korean J Radiol       Date:  2020-07       Impact factor: 3.500

6.  Selection of Treatment Regimens for Recurrent Cervical Cancer.

Authors:  Xiaopei Chao; Xiaochen Song; Huanwen Wu; Yan You; Ming Wu; Lei Li
Journal:  Front Oncol       Date:  2021-02-02       Impact factor: 6.244

7.  Calculating the overall survival probability in patients with cervical cancer: a nomogram and decision curve analysis-based study.

Authors:  Guilan Xie; Ruiqi Wang; Li Shang; Cuifang Qi; Liren Yang; Liyan Huang; Wenfang Yang; Mei Chun Chung
Journal:  BMC Cancer       Date:  2020-09-01       Impact factor: 4.430

8.  Intensity-modulated radiation therapy (IMRT)-based concurrent chemoradiotherapy (CCRT) with Endostar in patients with pelvic locoregional recurrence of cervical cancer: Results from a hospital in the Qinghai-Tibet Plateau.

Authors:  Kuan Zhang; Huiping Wang; Zhenqing Wang; Fuqing Li; Ying Cui; Shengchun Ma; Rui Chen; Yuhui Wang; Shul Guo; Ying Wei
Journal:  Medicine (Baltimore)       Date:  2020-12-04       Impact factor: 1.817

9.  miR-200a/b/-429 downregulation is a candidate biomarker of tumor radioresistance and independent of hypoxia in locally advanced cervical cancer.

Authors:  Anja Nilsen; Tiril Hillestad; Vilde E Skingen; Eva-Katrine Aarnes; Christina S Fjeldbo; Tord Hompland; Tina Sandø Evensen; Trond Stokke; Gunnar B Kristensen; Beata Grallert; Heidi Lyng
Journal:  Mol Oncol       Date:  2022-02-15       Impact factor: 6.603

10.  Identifying Critical States of Complex Diseases by Single-Sample Jensen-Shannon Divergence.

Authors:  Jinling Yan; Peiluan Li; Rong Gao; Ying Li; Luonan Chen
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.